Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.India-based pharmaceutical company Jubilant Organosys has announced that its subsidiary Jubilant Biosys based in Bangalore, India, has developed a next generation screening solution, Legend NGSS that will further enable the process of high throughput screening, accelerating global drug discovery.
Subscribe to our email newsletter
Jubilant has said that the software to be launched in the US and Europe initially, allows scientists to capture, store, and analyze Oracle 9i/10g based screening data with greater flexibility, accuracy and speed.
According to Jubilant, the Legend NGSS allows users to create rich visualization and interactive analysis reports, including dose-response curves and scatter plot heat maps. The novel tool allows flexible and interactive mother to daughter plate mapping from any plate reader. This generates best-fit kinetic and time course assays, without internal IT intervention, complete management of compound and targeted libraries, and optimized on-the fly curve-fitting techniques.
Legend NGSS is available worldwide on a subscription basis, which includes comprehensive software support and training. The product has generated substantial interest and response during prelaunch activities from global pharmaceutical companies involved in drug discovery, the company said.
Christoph Pittius, vice president of global business development at Jubilant Biosys, said: This novel screening tool for scientific, pharmaceutical and biotech communities around the world can enhance the productivity of pharmaceutical and biotech research. This innovative product demonstrates Jubilant’s strategy to develop and provide enabling technologies to accelerate the process of drug discovery and development.